Compare · BNTX vs MAZE
BNTX vs MAZE
Side-by-side comparison of BioNTech SE (BNTX) and Maze Therapeutics Inc. (MAZE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and MAZE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $24.78B, about 16.9x MAZE ($1.46B).
- Over the past year, BNTX is down 4.4% and MAZE is up 51.2% - MAZE leads by 55.6 points.
- MAZE has been more active in the news (15 items in the past 4 weeks vs 8 for BNTX).
- BNTX has more recent analyst coverage (25 ratings vs 7 for MAZE).
- Company
- BioNTech SE
- Maze Therapeutics Inc.
- Price
- $97.58-1.17%
- $24.60-6.71%
- Market cap
- $24.78B
- $1.46B
- 1M return
- +5.16%
- -8.96%
- 1Y return
- -4.41%
- +51.17%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2025
- News (4w)
- 8
- 15
- Recent ratings
- 25
- 7
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Latest BNTX
- Chief Executive Officer Sahin Ugur sold $7,889,055 worth of Ordinary Shares (76,500 units at $103.12) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 781,709 units (SEC Form 4)
- BioNTech downgraded by BMO Capital Markets with a new price target
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
- SEC Form 6-K filed by BioNTech SE
- BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
Latest MAZE
- President, R&D & CMO Bernstein Harold sold $254,502 worth of shares (9,705 units at $26.22) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- GC and Corp. Secretary Courtney Phillips converted options into 11,000 shares (SEC Form 4)
- Chief Executive Officer Coloma Jason V sold $906,999 worth of shares (34,501 units at $26.29) as part of a pre-agreed trading plan and converted options into 50,000 shares (SEC Form 4)
- CSBO Dandekar Atul converted options into 12,500 shares, increasing direct ownership by 48% to 38,750 units (SEC Form 4)
- President, R&D & CMO Bernstein Harold exercised 36,141 shares at a strike of $4.65 and sold $425,512 worth of shares (16,141 units at $26.36) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Maze Therapeutics Inc.
- SEC Form 144 filed by Maze Therapeutics Inc.
- Maze Therapeutics to Participate in Three Upcoming Investor Conferences
- SEC Form 144 filed by Maze Therapeutics Inc.
- CSBO Dandekar Atul sold $206,824 worth of shares (7,500 units at $27.58) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $10.42 (SEC Form 4)